Author

A. Raman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Terranova· 2 shared E. Orouji· 2 shared K. Rai· 2 shared M. Maitituoheti· 2 shared M. Tang· 2 shared S. Amin· 2 shared S. Sarkar· 2 shared W.-L. Wang· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Terranova

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis lesion and disease evolution

C. M. Langseth, P. Kukanja, L. A. R. Rodriguez-Kirby, E. Agirre, A. Raman, C. Yokota, C. Avenel, K. Tiklova, A. O. Guerreiro-Cacais, T. Olsson, M. M. Hilscher, M. Nilsson, G. Castelo-Branco

This study uses single-cell spatial sequencing to analyze MS lesion dynamics in mice and humans, revealing centrifugal lesion propagation and dynamic disease-associated glia.

bioRxiv · Jun 29, 2023Cell Biology

A Microfluidic Platform for Functional Testing of Cancer Drugs on Intact Tumor Slices

A. D. Rodriguez, L. F. Horowitz, K. Castro, H. Kenerson, N. Bhattacharjee, G. Gandhe, A. Raman, R. J. Monnat, R. S. Yeung, R. C. Rostomily, A. Folch

This paper develops a microfluidic platform for testing cancer drugs on intact tumor slices to improve drug response assessment in precision oncology.

bioRxiv · Mar 2, 2020Bioengineering

Bivalent and Broad Chromatin Domains Regulate Pro-metastatic Drivers in Melanoma

C. Terranova, M. Tang, M. Maitituoheti, A. Raman, J. Schulz, S. Amin, E. Orouji, K. Tomczak, S. Sarkar, J. Oba, C. Creasy, C.-J. Wu, D. Zhao, K. Chen, L. E. Haydu, , K. Rai

The paper identifies bivalent chromatin states and broad H3K4me3 domains associated with pro-metastatic drivers in melanoma using ChIP-sequencing data from tumor samples and cell lines.

bioRxiv · Aug 1, 2019 · PreprintCancer Biology

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma

M. Maitituoheti, E. Keung, M. Tang, L. Yan, H. Alam, G. Han, A. Raman, C. Terranova, S. Sarkar, E. Orouji, S. Amin, S. Sharma, M. Williams, N. S. Samant, M. Dhamdhere, , K. Rai

This study identifies KMT2D as a tumor suppressor in melanoma, showing its loss leads to metabolic reprogramming toward glycolysis and dependence on IGF signaling, suggesting therapeutic targeting of these pathways.

bioRxiv · Dec 27, 2018Cancer Biology